Copyright
©The Author(s) 2004.
World J Gastroenterol. Nov 15, 2004; 10(22): 3269-3273
Published online Nov 15, 2004. doi: 10.3748/wjg.v10.i22.3269
Published online Nov 15, 2004. doi: 10.3748/wjg.v10.i22.3269
Table 4 Comparison of noninvasive markers of hepatic fibrosis
| Group | Distinctly effective | Effective | Ineffect-ive | Comparison between 2 groups | |
| Statitics χ2 | P | ||||
| A | 2 | 42 | 22 | ||
| (n = 66) | (3.03%) | (63.64%) | (33.33%) | ||
| B | 0 | 20 | 46 | 16.2494 | 0.0001 |
| (n = 66) | (0.00%) | (30.30%) | (69.70%) | ||
- Citation: Mao YM, Zeng MD, Lu LG, Wan MB, Li CZ, Chen CW, Fu QC, Wang JY, She WM, Cai X, Ye J, Zhou XQ, Wang H, Wu SM, Tang MF, Zhu JS, Chen WX, Zhang HQ. Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: A randomized, double blind, placebo-controlled, multicenter clinical study. World J Gastroenterol 2004; 10(22): 3269-3273
- URL: https://www.wjgnet.com/1007-9327/full/v10/i22/3269.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i22.3269